Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNAseq analysis of PS+ vs PS- non-naive CD8 T cells sorted from peripheral blood of COVID-19 patients

ABSTRACT: RNAseq analysis of PS+ vs PS- non-naive CD8 T cells sorted from peripheral blood of COVID-19 patients

PROVIDER: PRJNA731518 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14607635.fastq.gz	Fastqsanger.gz
	SRR14607636.fastq.gz	Fastqsanger.gz
	SRR14607637.fastq.gz	Fastqsanger.gz
	SRR14607638.fastq.gz	Fastqsanger.gz
	SRR14607639.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

RNAseq analysis of PS+ vs PS- non-naive CD8 T cells sorted from peripheral blood of COVID-19 patients

Project description:We report the transcriptional profile of phosphatidylserine (PS) positive and PS negative non-naive peripheral blood CD8 T cells from patients infected with SARS-CoV-2. PS+ CD8 T cells showed increased expression of cell cyclce and cell division associated genes and reduced expression of genes regulating translational initiation, when compared to PS- CD 8 T cells. Furthermore, PS+ CD8 T cells show increased expression of effector T cell genes.

2021-05-21 | GSE174786 | GEO

RNAseq analysis of PS+ vs. PS- effector CD8 T cells sorted from spleen of LCMV-Armstrong infected mice

Project description:We report the transcriptional profile of phosphatidylserine (PS) positive and PS negative CD44+CD62L- effector CD8+ T cells from LCMV-Armstrong infected mice sorted from spleens on day5 amd day10 after infection. PS was stained in vivo by injection of MFG-E8-eGFP. PS+ cells acquire PS through binding of extracellular vesicles (EVs). Binding of EVs by effector CD8+ T cells is strongly enhanced during LCMV infection and peaks between day5 and day10 post infection. Effector T cell gene signature is increased in EV+ CD8+ T cells compared to their EV- counterparts.

2023-03-29 | GSE201507 | GEO

Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae

Project description:Post-acute sequelae of COVID-19 (PASC) represent an emerging global crisis. However, quantifiable risk-factors for PASC and their biological associations are poorly resolved. We executed a deep multi-omic, longitudinal investigation of 309 COVID-19 patients from initial diagnosis to convalescence (2-3 months later), integrated with clinical data, and patient-reported symptoms. We resolved four PASC-anticipating risk factors at the time of initial COVID-19 diagnosis: type 2 diabetes, SARS-CoV-2 RNAemia, Epstein-Barr virus viremia, and specific autoantibodies. In patients with gastrointestinal PASC, SARS-CoV-2-specific and CMV-specific CD8+ T cells exhibited unique dynamics during recovery from COVID-19. Analysis of symptom-associated immunological signatures revealed coordinated immunity polarization into four endotypes exhibiting divergent acute severity and PASC. We find that immunological associations between PASC factors diminish over time leading to distinct convalescent immune states. Detectability of most PASC factors at COVID-19 diagnosis emphasizes the importance of early disease measurements for understanding emergent chronic conditions and suggests PASC treatment strategies.

2022-02-01 | E-MTAB-10129 | biostudies-arrayexpress

SnoRNAs and miRNAs expression profiles underlying COVID-19 disease severity

Project description:The causative organism, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), exhibits a wide spectrum of clinical manifestations in disease-ridden patients. Differences in the severity of COVID-19 ranges from asymptomatic infections and mild cases to the severe form, leading to acute respiratory distress syndrome (ARDS) and multiorgan failure with poor survival. MiRNAs can regulate various cellular processes, including proliferation, apoptosis, and differentiation, by binding to the 3′UTR of target mRNAs inducing their degradation, thus serving a fundamental role in post-transcriptional repression. Alterations of miRNA levels in the blood have been described in multiple inflammatory and infectious diseases, including SARS-related coronaviruses. We used microarrays to delineate the miRNAs and snoRNAs signature in the peripheral blood of severe COVID-19 cases (n=9), as compared to mild (n=10) and asymptomatic (n=10) patients, and identified differentially expressed transcripts in severe versus asymptomatic, and others in severe versus mild COVID-19 cases. A cohort of 29 male age-matched patients were selected. All patients were previously diagnosed with COVID-19 using TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific, Waltham, Massachusetts), or Cobas SARS-CoV-2 Test (Roche Diagnostics, Rotkreuz, Switzerland), with a CT value < 30. Additional criterion for selection was age between 35 and 75 years. Participants were grouped into severe, mild and asymptomatic. Classifying severe cases was based on requirement of high-flow oxygen support and ICU admission (n=9). Whereas mild patients were identified based on symptoms and positive radiographic findings with pulmonary involvement (n=10). Patients with no clinical presentation were labelled as asymptomatic cases (n=10).

2022-03-01 | E-MTAB-10970 | biostudies-arrayexpress

RNA-seq of RBC depleted whole blood from COVID-19 patients and controls

Project description:Red blood cells (RBC) depleted whole blood from COVID-19 patients and controls was harvested and processed in order to performed 10X single cell RNA-seq. For COVID-19 patients 2 samples 10 days a part were analyzed.

2020-08-21 | E-MTAB-9221 | biostudies-arrayexpress

Gene expression profile of peripheral blood mononuclear cells from mild and severe COVID-19 patients, severely ill COVID-19 patients treated with dexamethasone and healthy controls

Project description:The objective of this experiment was to compare the transcriptomic profile (NanoString platform) of peripheral blood mononuclear cells (PBMCs) from COVID-19 patients with mild disease, and patients with severe COVID-19 with and without dexamethasone treatment, and healthy controls. We analyzed PBMCs from 4 mild COVID patients, 3 severe COVID patients,4 severe COVID patients treated with dexamethasone, and 5 healthy controls

2023-03-23 | GSE227341 | GEO

Methanococcus voltae PS strain:PS

Project description:Methanococcus voltae PS transcriptome - H25-1-PS

| PRJNA1387537 | ENA

Methanococcus voltae PS strain:PS

Project description:Methanococcus voltae PS transcriptome - H37-2-PS

| PRJNA1387540 | ENA

Methanococcus voltae PS strain:PS

Project description:Methanococcus voltae PS transcriptome - H37-3-PS

| PRJNA1387542 | ENA

Methanococcus voltae PS strain:PS

Project description:Methanococcus voltae PS transcriptome - H37-4-PS